[Treatment of erythema nodosum leprosum using thalidomide]. 1983

J Sheskin

UI MeSH Term Description Entries
D007917 Leprostatic Agents Substances that suppress Mycobacterium leprae, ameliorate the clinical manifestations of leprosy, and/or reduce the incidence and severity of leprous reactions. Antileprotic Agents,Leprostatics,Agents, Antileprotic,Agents, Leprostatic
D009431 Neural Conduction The propagation of the NERVE IMPULSE along the nerve away from the site of an excitation stimulus. Nerve Conduction,Conduction, Nerve,Conduction, Neural,Conductions, Nerve,Conductions, Neural,Nerve Conductions,Neural Conductions
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004893 Erythema Nodosum An erythematous eruption commonly associated with drug reactions or infection and characterized by inflammatory nodules that are usually tender, multiple, and bilateral. These nodules are located predominantly on the shins with less common occurrence on the thighs and forearms. They undergo characteristic color changes ending in temporary bruise-like areas. This condition usually subsides in 3-6 weeks without scarring or atrophy.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013792 Thalidomide A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action. Sedoval,Thalomid
D015440 Leprosy, Lepromatous A chronic communicable infection which is a principal or polar form of LEPROSY. This disorder is caused by MYCOBACTERIUM LEPRAE and produces diffuse granulomatous skin lesions in the form of nodules, macules, or papules. The peripheral nerves are involved symmetrically and neural sequelae occur in the advanced stage. Leprosy, Cutaneous,Leprosy, Nodular,Cutaneous Leprosies,Cutaneous Leprosy,Lepromatous Leprosies,Lepromatous Leprosy,Leprosies, Cutaneous,Leprosies, Lepromatous,Leprosies, Nodular,Nodular Leprosies,Nodular Leprosy

Related Publications

J Sheskin
September 1973, Lancet (London, England),
J Sheskin
August 1973, Lancet (London, England),
J Sheskin
May 1990, DICP : the annals of pharmacotherapy,
J Sheskin
June 1988, Leprosy review,
J Sheskin
November 1973, Lancet (London, England),
J Sheskin
October 1973, Lancet (London, England),
J Sheskin
October 2001, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
J Sheskin
October 2009, Therapeutic drug monitoring,
Copied contents to your clipboard!